Literature DB >> 17371972

Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells.

Jichun Chen1, Felicia M Ellison, Michael A Eckhaus, Aleah L Smith, Keyvan Keyvanfar, Rodrigo T Calado, Neal S Young.   

Abstract

Human bone marrow (BM) failure mediated by the immune system can be modeled in mice. In the present study, infusion of lymph node (LN) cells from C57BL/6 mice into C.B10-H2(b)/LilMcd (C.B10) recipients that are mismatched at multiple minor histocompatibility Ags, including the immunodominant Ag H60, produced fatal aplastic anemia. Declining blood counts correlated with marked expansion and activation of CD8 T cells specific for the immunodominant minor histocompatibility Ag H60. Infusion of LN cells from H60-matched donors did not produce BM failure in C.B10 mice, whereas isolated H60-specific CTL were cytotoxic for normal C.B10 BM cells in vitro. Treatment with the immunosuppressive drug cyclosporine abolished H60-specific T cell expansion and rescued animals from fatal pancytopenia. The development of BM failure was associated with a significant increase in activated CD4+CD25+ T cells that did not express intracellular FoxP3, whereas inclusion of normal CD4+CD25+ regulatory T cells in combination with C57BL/6 LN cells aborted H60-specific T cell expansion and prevented BM destruction. Thus, a single minor histocompatibility Ag H60 mismatch can trigger an immune response leading to massive BM destruction. Immunosuppressive drug treatment or enhancement of regulatory T cell function abrogated this pathophysiology and protected animals from the development of BM failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371972     DOI: 10.4049/jimmunol.178.7.4159

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  MHC class II upregulation and colocalization with Fas in experimental models of immune-mediated bone marrow failure.

Authors:  Andrew J Erie; Leigh Samsel; Tomoiku Takaku; Marie J Desierto; Keyvan Keyvanfar; J Philip McCoy; Neal S Young; Jichun Chen
Journal:  Exp Hematol       Date:  2011-05-13       Impact factor: 3.084

Review 2.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

3.  Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy.

Authors:  Tomoiku Takaku; Daniela Malide; Jichun Chen; Rodrigo T Calado; Sachiko Kajigaya; Neal S Young
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

4.  Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

Authors:  Michael A Pulsipher; Neal S Young; Jakub Tolar; Antonio M Risitano; H Joachim Deeg; Paolo Anderlini; Rodrigo Calado; Seiji Kojima; Mary Eapen; Richard Harris; Phillip Scheinberg; Sharon Savage; Jaroslaw P Maciejewski; Ramon V Tiu; Nancy DiFronzo; Mary M Horowitz; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-27       Impact factor: 5.742

5.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

Review 6.  New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia.

Authors:  Wendy Weston; Vineet Gupta; Rebecca Adkins; Roland Jurecic
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

7.  Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice.

Authors:  Qing Tong; Shan He; Fang Xie; Kazuhiro Mochizuki; Yongnian Liu; Izumi Mochizuki; Lijun Meng; Hongxing Sun; Yanyun Zhang; Yajun Guo; Elizabeth Hexner; Yi Zhang
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

8.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

9.  The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure.

Authors:  Yong Tang; Marie J Desierto; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

10.  IFN-γ-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure.

Authors:  Jichun Chen; Xingmin Feng; Marie J Desierto; Keyvan Keyvanfar; Neal S Young
Journal:  Blood       Date:  2015-10-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.